Sun Pharma Global FZE to return product rights back to SPARC

16 Feb 2019 Evaluate

Sun Pharma Advanced Research Company (SPARC) has received a communication from Sun Pharma Global FZE (SPGFZE), a wholly owned subsidiary of Sun Pharmaceutical Industries that it has decided to return the product rights back to SPARC.

SPGFZE is not planning to launch Elepsia XR (Levetiracetam Extended Release Tablets) as CNS is not its focussed therapeutic area in US market.
Earlier, SPARC had out-licensed ELEPSIA XR to SPGFZE in July 2016; and was eligible for sales linked milestone and royalties upon commercialization of Elepsia TM XR. Consequently, SPARC would find another partner for commercialising the captioned product.

SPARC is an international pharmaceutical company engaged in research and development of drugs and delivery systems.

Sun Pharma Adv. Res Share Price

134.70 -0.30 (-0.22%)
02-Jan-2026 09:21 View Price Chart
Peers
Company Name CMP
Syngene Internation. 650.65
Indegene 519.55
CMS Info Systems 348.20
Sagility 52.24
Smartworks Coworking 517.80
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×